NASDAQ:TVTX

Travere Therapeutics Competitors

$24.95
-0.99 (-3.82 %)
(As of 04/16/2021 12:00 AM ET)
Add
Compare
Today's Range
$24.38
Now: $24.95
$26.46
50-Day Range
$23.37
MA: $26.61
$30.82
52-Week Range
$12.82
Now: $24.95
$33.09
Volume690,741 shs
Average Volume598,872 shs
Market Capitalization$1.51 billion
P/E RatioN/A
Dividend YieldN/A
Beta0.77

Competitors

Travere Therapeutics (NASDAQ:TVTX) Vs. IONS, SRPT, PRGO, ALLK, BPMC, and SDGR

Should you be buying TVTX stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Travere Therapeutics, including Ionis Pharmaceuticals (IONS), Sarepta Therapeutics (SRPT), Perrigo (PRGO), Allakos (ALLK), Blueprint Medicines (BPMC), and Schrödinger (SDGR).

Travere Therapeutics (NASDAQ:TVTX) and Ionis Pharmaceuticals (NASDAQ:IONS) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, analyst recommendations, institutional ownership, valuation, dividends, earnings and profitability.

Volatility and Risk

Travere Therapeutics has a beta of 0.77, meaning that its stock price is 23% less volatile than the S&P 500. Comparatively, Ionis Pharmaceuticals has a beta of 1.42, meaning that its stock price is 42% more volatile than the S&P 500.

Profitability

This table compares Travere Therapeutics and Ionis Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Travere Therapeutics-40.24%-29.27%-12.25%
Ionis Pharmaceuticals7.82%6.57%3.39%

Analyst Ratings

This is a breakdown of recent ratings for Travere Therapeutics and Ionis Pharmaceuticals, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Travere Therapeutics00503.00
Ionis Pharmaceuticals27602.27

Travere Therapeutics presently has a consensus target price of $44.3333, indicating a potential upside of 77.69%. Ionis Pharmaceuticals has a consensus target price of $57.9091, indicating a potential upside of 42.00%. Given Travere Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe Travere Therapeutics is more favorable than Ionis Pharmaceuticals.

Valuation & Earnings

This table compares Travere Therapeutics and Ionis Pharmaceuticals' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Travere Therapeutics$175.34 million8.60$-146,430,000.00($3.46)-7.21
Ionis Pharmaceuticals$1.12 billion5.12$303.26 million$2.0819.61

Ionis Pharmaceuticals has higher revenue and earnings than Travere Therapeutics. Travere Therapeutics is trading at a lower price-to-earnings ratio than Ionis Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

84.1% of Ionis Pharmaceuticals shares are held by institutional investors. 4.6% of Travere Therapeutics shares are held by insiders. Comparatively, 2.4% of Ionis Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Ionis Pharmaceuticals beats Travere Therapeutics on 10 of the 14 factors compared between the two stocks.

Travere Therapeutics (NASDAQ:TVTX) and Sarepta Therapeutics (NASDAQ:SRPT) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, analyst recommendations, institutional ownership, valuation, dividends, earnings and profitability.

Volatility and Risk

Travere Therapeutics has a beta of 0.77, meaning that its stock price is 23% less volatile than the S&P 500. Comparatively, Sarepta Therapeutics has a beta of 2.01, meaning that its stock price is 101% more volatile than the S&P 500.

Profitability

This table compares Travere Therapeutics and Sarepta Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Travere Therapeutics-40.24%-29.27%-12.25%
Sarepta Therapeutics-121.30%-61.62%-23.02%

Analyst Ratings

This is a breakdown of recent ratings for Travere Therapeutics and Sarepta Therapeutics, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Travere Therapeutics00503.00
Sarepta Therapeutics191302.52

Travere Therapeutics presently has a consensus target price of $44.3333, indicating a potential upside of 77.69%. Sarepta Therapeutics has a consensus target price of $150.4762, indicating a potential upside of 109.58%. Given Sarepta Therapeutics' higher probable upside, analysts clearly believe Sarepta Therapeutics is more favorable than Travere Therapeutics.

Valuation & Earnings

This table compares Travere Therapeutics and Sarepta Therapeutics' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Travere Therapeutics$175.34 million8.60$-146,430,000.00($3.46)-7.21
Sarepta Therapeutics$380.83 million14.97$-715,080,000.00($9.71)-7.39

Travere Therapeutics has higher earnings, but lower revenue than Sarepta Therapeutics. Sarepta Therapeutics is trading at a lower price-to-earnings ratio than Travere Therapeutics, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

89.7% of Sarepta Therapeutics shares are held by institutional investors. 4.6% of Travere Therapeutics shares are held by insiders. Comparatively, 5.9% of Sarepta Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Sarepta Therapeutics beats Travere Therapeutics on 8 of the 14 factors compared between the two stocks.

Travere Therapeutics (NASDAQ:TVTX) and Perrigo (NYSE:PRGO) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, analyst recommendations, institutional ownership, valuation, dividends, earnings and profitability.

Volatility and Risk

Travere Therapeutics has a beta of 0.77, meaning that its stock price is 23% less volatile than the S&P 500. Comparatively, Perrigo has a beta of 1.18, meaning that its stock price is 18% more volatile than the S&P 500.

Profitability

This table compares Travere Therapeutics and Perrigo's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Travere Therapeutics-40.24%-29.27%-12.25%
Perrigo-0.13%9.78%4.92%

Analyst Ratings

This is a breakdown of recent ratings for Travere Therapeutics and Perrigo, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Travere Therapeutics00503.00
Perrigo04102.20

Travere Therapeutics presently has a consensus target price of $44.3333, indicating a potential upside of 77.69%. Perrigo has a consensus target price of $52.00, indicating a potential upside of 24.94%. Given Travere Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe Travere Therapeutics is more favorable than Perrigo.

Valuation & Earnings

This table compares Travere Therapeutics and Perrigo's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Travere Therapeutics$175.34 million8.60$-146,430,000.00($3.46)-7.21
Perrigo$4.84 billion1.15$146.10 million$4.0310.33

Perrigo has higher revenue and earnings than Travere Therapeutics. Travere Therapeutics is trading at a lower price-to-earnings ratio than Perrigo, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

82.7% of Perrigo shares are held by institutional investors. 4.6% of Travere Therapeutics shares are held by insiders. Comparatively, 0.3% of Perrigo shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Perrigo beats Travere Therapeutics on 8 of the 14 factors compared between the two stocks.

Travere Therapeutics (NASDAQ:TVTX) and Allakos (NASDAQ:ALLK) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, analyst recommendations, institutional ownership, valuation, dividends, earnings and profitability.

Volatility and Risk

Travere Therapeutics has a beta of 0.77, meaning that its stock price is 23% less volatile than the S&P 500. Comparatively, Allakos has a beta of 1.02, meaning that its stock price is 2% more volatile than the S&P 500.

Profitability

This table compares Travere Therapeutics and Allakos' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Travere Therapeutics-40.24%-29.27%-12.25%
AllakosN/A-29.18%-27.70%

Analyst Ratings

This is a breakdown of recent ratings for Travere Therapeutics and Allakos, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Travere Therapeutics00503.00
Allakos00403.00

Travere Therapeutics presently has a consensus target price of $44.3333, indicating a potential upside of 77.69%. Allakos has a consensus target price of $181.50, indicating a potential upside of 73.68%. Given Travere Therapeutics' higher probable upside, research analysts clearly believe Travere Therapeutics is more favorable than Allakos.

Valuation & Earnings

This table compares Travere Therapeutics and Allakos' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Travere Therapeutics$175.34 million8.60$-146,430,000.00($3.46)-7.21
AllakosN/AN/A$-85,370,000.00($1.89)-55.29

Allakos has lower revenue, but higher earnings than Travere Therapeutics. Allakos is trading at a lower price-to-earnings ratio than Travere Therapeutics, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

65.4% of Allakos shares are held by institutional investors. 4.6% of Travere Therapeutics shares are held by insiders. Comparatively, 44.8% of Allakos shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Allakos beats Travere Therapeutics on 7 of the 12 factors compared between the two stocks.

Travere Therapeutics (NASDAQ:TVTX) and Blueprint Medicines (NASDAQ:BPMC) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, analyst recommendations, institutional ownership, valuation, dividends, earnings and profitability.

Volatility and Risk

Travere Therapeutics has a beta of 0.77, suggesting that its stock price is 23% less volatile than the S&P 500. Comparatively, Blueprint Medicines has a beta of 0.92, suggesting that its stock price is 8% less volatile than the S&P 500.

Profitability

This table compares Travere Therapeutics and Blueprint Medicines' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Travere Therapeutics-40.24%-29.27%-12.25%
Blueprint Medicines41.08%43.72%33.35%

Analyst Ratings

This is a breakdown of recent ratings for Travere Therapeutics and Blueprint Medicines, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Travere Therapeutics00503.00
Blueprint Medicines06812.67

Travere Therapeutics presently has a consensus target price of $44.3333, indicating a potential upside of 77.69%. Blueprint Medicines has a consensus target price of $112.40, indicating a potential upside of 18.07%. Given Travere Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe Travere Therapeutics is more favorable than Blueprint Medicines.

Valuation & Earnings

This table compares Travere Therapeutics and Blueprint Medicines' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Travere Therapeutics$175.34 million8.60$-146,430,000.00($3.46)-7.21
Blueprint Medicines$66.51 million82.96$-347,690,000.00($7.27)-13.09

Travere Therapeutics has higher revenue and earnings than Blueprint Medicines. Blueprint Medicines is trading at a lower price-to-earnings ratio than Travere Therapeutics, indicating that it is currently the more affordable of the two stocks.

Summary

Blueprint Medicines beats Travere Therapeutics on 8 of the 13 factors compared between the two stocks.

Travere Therapeutics (NASDAQ:TVTX) and Schrödinger (NASDAQ:SDGR) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, earnings, dividends, institutional ownership, valuation, risk and profitability.

Institutional & Insider Ownership

41.3% of Schrödinger shares are owned by institutional investors. 4.6% of Travere Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares Travere Therapeutics and Schrödinger's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Travere Therapeutics-40.24%-29.27%-12.25%
Schrödinger-19.92%-7.25%-5.33%

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Travere Therapeutics and Schrödinger, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Travere Therapeutics00503.00
Schrödinger01302.75

Travere Therapeutics currently has a consensus target price of $44.3333, indicating a potential upside of 77.69%. Schrödinger has a consensus target price of $85.50, indicating a potential upside of 9.76%. Given Travere Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe Travere Therapeutics is more favorable than Schrödinger.

Earnings and Valuation

This table compares Travere Therapeutics and Schrödinger's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Travere Therapeutics$175.34 million8.60$-146,430,000.00($3.46)-7.21
Schrödinger$85.54 million63.76$-24,570,000.00N/AN/A

Schrödinger has lower revenue, but higher earnings than Travere Therapeutics.

Summary

Schrödinger beats Travere Therapeutics on 6 of the 11 factors compared between the two stocks.


Travere Therapeutics Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Ionis Pharmaceuticals logo
IONS
Ionis Pharmaceuticals
1.6$40.78-0.6%$5.74 billion$1.12 billion84.96Analyst Revision
Sarepta Therapeutics logo
SRPT
Sarepta Therapeutics
1.9$71.80-1.2%$5.70 billion$380.83 million-9.18Analyst Report
Perrigo logo
PRGO
Perrigo
2.3$41.62-1.1%$5.56 billion$4.84 billion-693.55
Allakos logo
ALLK
Allakos
1.7$104.50-3.5%$5.55 billionN/A-38.14Insider Selling
Gap Down
Blueprint Medicines logo
BPMC
Blueprint Medicines
1.5$95.20-0.8%$5.52 billion$66.51 million17.56Analyst Report
Analyst Revision
News Coverage
Schrödinger logo
SDGR
Schrödinger
1.3$77.90-0.6%$5.45 billion$85.54 million0.00Insider Selling
News Coverage
Galapagos logo
GLPG
Galapagos
1.3$79.15-0.3%$5.19 billion$1.00 billion-11.99Analyst Upgrade
Biohaven Pharmaceutical logo
BHVN
Biohaven Pharmaceutical
2.0$74.40-1.9%$4.62 billionN/A-6.06Analyst Revision
Gap Down
Sage Therapeutics logo
SAGE
Sage Therapeutics
1.4$74.64-1.2%$4.36 billion$6.87 million-7.21Unusual Options Activity
Analyst Revision
Hutchison China MediTech logo
HCM
Hutchison China MediTech
1.4$29.25-0.4%$4.26 billion$204.89 million-36.56
Emergent BioSolutions logo
EBS
Emergent BioSolutions
2.0$77.64-4.1%$4.16 billion$1.11 billion24.96Analyst Report
Gap Up
I-Mab logo
IMAB
I-Mab
1.2$57.00-0.2%$4.10 billion$4.31 million-1.97Increase in Short Interest
Arena Pharmaceuticals logo
ARNA
Arena Pharmaceuticals
1.7$65.90-3.2%$3.98 billion$806.43 million-9.33Analyst Report
Agios Pharmaceuticals logo
AGIO
Agios Pharmaceuticals
1.3$54.69-0.6%$3.82 billion$117.91 million-11.09News Coverage
Atea Pharmaceuticals logo
AVIR
Atea Pharmaceuticals
2.0$44.94-2.4%$3.72 billionN/A0.00Analyst Report
Increase in Short Interest
News Coverage
Apellis Pharmaceuticals logo
APLS
Apellis Pharmaceuticals
1.6$45.57-1.8%$3.66 billionN/A-6.14Analyst Report
Analyst Revision
News Coverage
Gap Down
Turning Point Therapeutics logo
TPTX
Turning Point Therapeutics
1.7$73.03-5.8%$3.58 billionN/A-20.81Analyst Report
Nektar Therapeutics logo
NKTR
Nektar Therapeutics
1.5$19.00-1.9%$3.46 billion$114.62 million-7.66Analyst Report
Insider Selling
News Coverage
LEGN
Legend Biotech
1.2$26.00-0.8%$3.46 billion$64.39 million0.00Decrease in Short Interest
News Coverage
PTC Therapeutics logo
PTCT
PTC Therapeutics
1.3$48.59-0.8%$3.42 billion$306.98 million-6.95
Insmed logo
INSM
Insmed
1.2$33.07-1.7%$3.42 billion$136.47 million-12.72News Coverage
Gap Down
ACADIA Pharmaceuticals logo
ACAD
ACADIA Pharmaceuticals
1.9$21.15-0.2%$3.38 billion$339.08 million-12.30Analyst Report
High Trading Volume
Reata Pharmaceuticals logo
RETA
Reata Pharmaceuticals
1.4$90.87-1.5%$3.29 billion$26.52 million-8.01
ChemoCentryx logo
CCXI
ChemoCentryx
1.6$46.54-1.3%$3.25 billion$36.13 million-69.46Gap Down
Alkermes logo
ALKS
Alkermes
1.2$19.87-0.5%$3.16 billion$1.17 billion-43.19Insider Selling
Arvinas logo
ARVN
Arvinas
1.5$64.69-2.6%$3.16 billion$42.98 million-25.27Analyst Upgrade
Karuna Therapeutics logo
KRTX
Karuna Therapeutics
1.8$112.60-4.2%$3.04 billionN/A-56.02Insider Selling
MorphoSys logo
MOR
MorphoSys
0.3$22.65-2.3%$2.98 billion$80.43 million107.86Decrease in Short Interest
OPKO Health logo
OPK
OPKO Health
1.9$4.34-0.5%$2.91 billion$901.90 million-24.11Gap Up
Taro Pharmaceutical Industries logo
TARO
Taro Pharmaceutical Industries
0.9$75.64-1.6%$2.89 billion$644.77 million-10.79
Pacira BioSciences logo
PCRX
Pacira BioSciences
2.1$63.07-5.2%$2.77 billion$421.03 million22.21Analyst Report
Insider Selling
High Trading Volume
News Coverage
Gap Up
Organogenesis logo
ORGO
Organogenesis
1.0$21.46-5.3%$2.75 billion$260.98 million-357.67Analyst Downgrade
Gap Down
Deciphera Pharmaceuticals logo
DCPH
Deciphera Pharmaceuticals
1.6$47.00-0.5%$2.71 billion$25 million-9.40Insider Selling
Rocket Pharmaceuticals logo
RCKT
Rocket Pharmaceuticals
1.4$43.39-0.9%$2.68 billionN/A-23.84
Corcept Therapeutics logo
CORT
Corcept Therapeutics
1.5$22.77-0.7%$2.67 billion$306.49 million25.58
Amicus Therapeutics logo
FOLD
Amicus Therapeutics
1.6$9.94-3.9%$2.63 billion$182.24 million-8.64Analyst Upgrade
Global Blood Therapeutics logo
GBT
Global Blood Therapeutics
1.4$40.81-1.3%$2.54 billion$2.11 million-8.83Analyst Report
Analyst Revision
Intra-Cellular Therapies logo
ITCI
Intra-Cellular Therapies
1.7$31.22-3.6%$2.53 billion$60,000.00-9.70
Ligand Pharmaceuticals logo
LGND
Ligand Pharmaceuticals
1.6$150.23-0.9%$2.50 billion$120.28 million-151.75Analyst Report
Decrease in Short Interest
Xencor logo
XNCR
Xencor
1.2$42.26-5.7%$2.45 billion$156.70 million-30.19
ALX Oncology logo
ALXO
ALX Oncology
1.9$60.73-0.6%$2.44 billionN/A0.00Analyst Report
Insider Selling
Increase in Short Interest
Cryoport logo
CYRX
Cryoport
1.9$51.57-2.6%$2.35 billion$33.94 million-88.91Gap Down
Arcus Biosciences logo
RCUS
Arcus Biosciences
2.0$33.13-5.6%$2.35 billion$15 million-17.35Unusual Options Activity
News Coverage
Gap Down
Prestige Consumer Healthcare logo
PBH
Prestige Consumer Healthcare
1.6$45.22-0.4%$2.25 billion$963.01 million14.04
Dicerna Pharmaceuticals logo
DRNA
Dicerna Pharmaceuticals
2.0$28.96-1.5%$2.21 billion$23.90 million-17.99Analyst Report
Unusual Options Activity
News Coverage
Gap Down
Zentalis Pharmaceuticals logo
ZNTL
Zentalis Pharmaceuticals
1.6$50.68-0.8%$2.08 billionN/A0.00Insider Selling
Analyst Revision
NGM Biopharmaceuticals logo
NGM
NGM Biopharmaceuticals
1.8$26.15-0.3%$2.01 billion$103.54 million-19.66Insider Selling
Madrigal Pharmaceuticals logo
MDGL
Madrigal Pharmaceuticals
1.7$124.77-1.5%$2.00 billionN/A-11.27
Axsome Therapeutics logo
AXSM
Axsome Therapeutics
1.4$53.44-1.6%$2.00 billionN/A-19.87
Amarin logo
AMRN
Amarin
1.6$5.02-0.2%$1.98 billion$429.76 million-100.38Analyst Revision
This page was last updated on 4/17/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.